🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Gaining Traction Via Social Media

The experimental drug, which remains in research studies, is being promoted by social media influencers for its alleged weight-reducing effects. Followers are urged to contact these profiles privately for supplier links, while also obtaining promotional offers.

Thriving Trade on Social Networks

Additionally, a robust trade exists on Telegram, where groups with numerous of members share “before and after” images, injection guides and claims of next-day British shipping. Vendors market the drug there before directing buyers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic.

Medical Experts Voice Concerns

However, physicians and pharmacists have warned that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in individuals injecting substances of unknown origin.

Several experts said the demand for retatrutide could be linked to the increasing cost of licensed weight loss treatments such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the British medical regulations.

Several content creators attempt to circumvent the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but promotion and distribution can still violate medicines, advertising, and customer regulations, risking fines, legal action or prison.

Platform Reaction and Material Removal

Based on TikTok, the service has taken down problematic content and prohibited associated hashtags and query recommendations. The organization said it was committed to keeping the service safe and allocating resources in enhancing compliance measures.

Digital Marketplace Operations

Investigations also discovered groups with up to 9,000 participants selling the experimental drug using the platform's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays groups with thousands of members, filled with images of weight loss, glowing testimonials and detailed instructions for preparing or administering at home.

Within minutes of joining one community, a seller posted contact information, where the majority of purchases take place. The seller provided an guidebook and promised shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None asked about body mass, medical conditions or previous experience.

Product Information and Costs

Within these communities, posts show black plastic packages with postal service stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with purified liquid, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When questioned how much time a injector should last, sellers give conflicting answers varying between a several days to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service stated it actively moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are administering materials they cannot confirm. Although the research behind this drug is sound, these digital products may not include what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, patients are using social media. But fake treatments are highly dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she explained.

Her staff has already encountered patients injured by personal administration from unverified sources. “We understand the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, adding that any item “falsely representing itself as a Lilly investigational substance not yet authorized … may subject patients to possibly significant medical dangers”.